Stockscreener 앱 받기
7.73
7.98%
-0.67
시간 외 거래:
7.73
전일 마감가:
$8.40
열려 있는:
$8.33
하루 거래량:
751.10K
Relative Volume:
1.39
시가총액:
$141.80M
수익:
$146.07M
순이익/손실:
$-196.04M
주가수익비율:
-0.4651
EPS:
-16.621
순현금흐름:
$-75.37M
1주 성능:
-2.15%
1개월 성능:
-20.06%
6개월 성능:
+42.88%
1년 성능:
+31.24%
1일 변동 폭
$7.73
$8.6151
1주일 범위
$7.29
$8.68
52주 변동 폭
$3.51
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
7.73 | 154.09M | 146.07M | -196.04M | -75.37M | -16.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
| 2026-02-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN
Karyopharm Therapeutics (KPTI) Price Target Decreased by 10.98% to 15.98 - MSN
Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead - MSN
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Update - MarketBeat
Rodman & Renshaw initiates coverage of Karyopharm Therapeutics (KPTI) with buy recommendation - MSN
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
KPTI: Rodman & Renshaw Initiates Coverage with a 'Buy' Rating | - GuruFocus
Rodman & Renshaw initiates Karyopharm stock with buy rating By Investing.com - Investing.com Canada
Will Karyopharm's SENTRY Trial Data Pave The Way For Selinexor Label Expansion? - RTTNews
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
CEO Moves: How liquid is Karyopharm Therapeutics Inc stock2025 Retail Activity & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Cantor Fitzgerald reiterates Karyopharm stock rating on trial outlook By Investing.com - Investing.com Canada
Analysts Are Bullish on These Healthcare Stocks: Evolus (EOLS), Aldeyra Therapeutics (ALDX) - The Globe and Mail
Tax-driven share sale by Karyopharm (KPTI) EVP Mano Michael disclosed - Stock Titan
Karyopharm (NASDAQ: KPTI) EVP sells shares for tax withholding - Stock Titan
Karyopharm (KPTI) EVP executes automatic share sale for tax withholding - Stock Titan
Karyopharm (KPTI) CEO executes automatic 12,361-share sale to cover RSU taxes - Stock Titan
Automatic tax-sale trims Karyopharm (NASDAQ: KPTI) EVP shareholdings - Stock Titan
Karyopharm Therapeutics Inc. 8-K Filing and Material Definitive Agreement (February 27, 2026) - Minichart
KPTI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Karyopharm Therapeutics Incon February 27, 2026, company enters second amendment to Credit AgreementSEC filing - marketscreener.com
Karyopharm Amends Credit Agreement to Extend Liquidity Runway - TipRanks
According to a filing submitted to the U.S. Securities and Exchange Commission (SEC), Karyopharm Therapeutics Inc. has obtained permission through an amended agreement to defer the payment deadline for certain amounts until September 2026. - Bitget
Karyopharm Therapeutics Amends Credit Agreement to Defer 2026 Payments, Tied to $25M Equity Raise - TradingView
[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity - Stock Titan
Karyopharm (KPTI) debt relief and forbearance depend on $25M stock sale - Stock Titan
Karyopharm Grants 1,450 RSUs to New Hires - National Today
Pharma company Karyopharm gives 1,450 stock units to two new hires - Stock Titan
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript - AOL.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Sees Significant Increase in Short Interest - MarketBeat
Karyopharm Therapeutics Target of Unusually Large Options Trading (NASDAQ:KPTI) - MarketBeat
KPTI Should I Buy - Intellectia AI
KPTIKaryopharm Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Karyopharm Therapeutics Shareholders Approve Plan to Nearly Double Authorized Shares at Special Meeting - Yahoo Finance
Earnings call transcript: Karyopharm sees 11.8% revenue rise in Q4 2025 - Investing.com Nigeria
New Highs: Should I set a stop loss on NVAXEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Karyopharm (KPTI) Rockets After Data Update: Is the Rebound Real? - AD HOC NEWS
HC Wainwright Brokers Lift Earnings Estimates for KPTI - MarketBeat
Can Karyopharm Therapeutics Inc. disrupt its industryJuly 2025 Price Swings & Stepwise Trade Signal Guides - mfd.ru
Karyopharm Shareholders Approve Major Authorized Share Increase - TipRanks
KPTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade - Zacks Investment Research
HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | - GuruFocus
Registration Momentum Builds Across the Oncology Pipeline - GlobeNewswire
Aug Movers: Can Karyopharm Therapeutics Inc disrupt its industry2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Estimates: Here's What Brokers Think Of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Its Full-Year Report - 富途牛牛
Analysts Have Made A Financial Statement On Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Annual Report - Yahoo Finance
Karyopharm Therapeutics Faces Rising Regulatory and Political Risks Amid Supreme Court Limits on FDA Authority - The Globe and Mail
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):